This suggests that GAS5 may serve as a more specific and potentially early biomarker for identifying individuals at risk of NAFLD before clinical diagnosis, offering advantages over traditional markers like LDL or BMI alone. Here, GAS5 is linked to metabolic dysfunction-associated steatotic liver disease.